Treatment Clinical Trials for Breast Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for breast cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 526-535 of 535
< Previous 1 ... 20 21 22

  • Copanlisib, Letrozole, and Palbociclib in Treating Patients with Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

    This phase I / II trial studies side effects and best dose of copanlisib when given together with letrozole and palbociclib and to see how well they work in treating hormone receptor positive HER2 negative stage I-IV breast cancer. Copanlisib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving copanlisib, letrozole, and palbociclib may work better in treating patients with breast cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • 18F-FBnTP Positron Emission Mammography in Detecting Breast Cancer in Patients with Intraductal Breast Cancer

    This phase I trial studies how well 18F-FBnTP positron emission mammography works in detecting breast cancer in patients with intraductal breast cancer. 18F-FBnTP positron emission mammography may detect may detect breast lesions with better sensitivity and better specificity.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Blood and Imaging Based Biomarkers in Patients with Estrogen Receptor Positive Stage 0-III Breast Cancer

    This pilot research trial studies the blood and imaging based biomarkers in patients with estrogen receptor positive stage 0-III breast cancer. Studying blood and imaging based biomarkers may help doctors to find potential indicators of those who are at risk of developing aromatase inhibitor-induced musculoskeletal syndrome.
    Location: 3 locations

  • Molecular Profile of Breast Cancer in Ugandan Patients with Stage IIB-III Breast Cancer

    This phase I trials studies the molecular profile of breast cancer in Ugandan patients with stage IIB-III breast cancer. Creating a molecular profile of breast cancer my help doctors learn more about biological factors associated with breast cancer in Ugandan patients with as well as measure the benefits of locally available diagnostic studies and the possibility of providing treatment via oral medication.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Carboplatin and Paclitaxel followed by Doxorubicin and Cyclophosphamide in Treating Patients with Triple Negative Breast Cancer

    This phase II trial studies how well carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide work in treating patients with triple negative breast cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 6 locations

  • Alisertib with or without Fulvestrant in Treating Patients with Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

    This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may work better in treating patients with breast cancer.
    Location: 9 locations

  • Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer

    This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.
    Location: See Clinical Trials.gov

  • Accelerated Partial Breast Irradiation Using Proton Beam Scanning before Surgery in Treating Patients with Triple-Negative Breast Cancer

    This pilot clinical trial studies the side effects of accelerated partial breast irradiation using proton beam scanning and to see how well it works before surgery in treating patients with triple-negative breast cancer. Accelerated partial breast irradiation using proton beam scanning administered in higher doses over a shorter time period may help stop cancer from growing while protecting normal tissue cells.
    Location: See Clinical Trials.gov

  • Nivolumab and Cabozantinib in Treating Patients with Metastatic Triple-Negative Breast Cancer

    This phase II trial studies how well nivolumab and cabozantinib work in treating patients with triple negative breast cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and cabozantinib may work better in treating patients with triple negative breast cancer.
    Location: See Clinical Trials.gov


< Previous 1 ... 20 21 22